| |
| EXCHANGE |
NASDAQ Global Market (.O) |
| SECURITY |
RIGL Common Stock |
 |
| INVESTMENT FIRM |
ANALYST NAME |
PHONE NUMBER |
| Jefferies & Company |
Thomas Wei |
|
| Oppenheimer & Co. Inc. |
Bret Holley Ph.D |
|
| Citi Investment Research |
Lucy Lu, M.D. |
|
| Collins Stewart |
Salveen Richter |
|
| J.P. Morgan Securities LLC |
Cory Kasimov |
|
| Piper Jaffray |
M. Ian Somaiya |
|
| Think Equity |
Marko Kozul, M.D. |
|
| Stifel, Nicolaus & Company, Inc. |
Stephen Willey |
|
| Wells Fargo Securities, LLC |
Brian Abrahams |
|
| BMO Capital Markets Corp. |
Jim Birchenough, M.D. |
|
| Rigel Pharmaceuticals Inc. is followed by the analyst(s) listed above.
Please note that any opinions, estimates or forecasts regarding Rigel Pharmaceuticals Inc.'s
performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions
of Rigel Pharmaceuticals Inc. or its management. Rigel Pharmaceuticals Inc.
does not by its reference above or distribution imply its endorsement of or concurrence with such information,
conclusions or recommendations.
|
|
|
